Featured Content

Dean Gesme, MD
FACP FACPE FASCO President, Minnesota Oncology

New Tools For Assessing Drug Value Haven’t Caught On With Payers — Yet

(STAT/Pharmalot) July 26, 2016 - As prices for prescription drugs keep rising, several organizations have developed different ways to assess the value of new medicines based on such attributes as cost, quality of life, and effectiveness. But a new survey finds that even as health plans continue to criticize drug prices, they have not yet embraced these new tools.

Commentary: This is not at all surprising as payers must come forth with policies immediately upon new drug approvals and cannot...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Half of Dermatologists Say They Weren't Trained to Spot Cancer on Black Skin

(New York Magazine/Science of Us) July 27, 2016 - There are so many damning statistics in a piece published this week by STAT, the health and science news site launched last fall by the Boston Globe, about racial disparities in health care.
read article »

Earliest Human Cancer Found in 1.7-Million-Year-Old Bone

(National Geographic) July 28, 2016 - The ancient toe from a human relative in South Africa could have important implications for modern medical research.
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



New Tools For Assessing Drug Value Haven’t Caught On With Payers — Yet (STAT/Pharmalot)

This is not at all surprising as payers must come forth with policies immediately upon new drug approvals and cannot...posted by: Dean Gesme, MD

Michael Kolodziej, M.D., a Leader in Oncology Value-based Care, Joins Flatiron Health to Lead Managed Care Strategy (Flatiron Health)

This is great news for community oncology! Mike has had a great career as an oncology provider, practice leader...posted by: Jeff Patton, M.D.

Oxaliplatin-Based Adjuvant Chemo for Stage III MMR CRC (Medscape Medical News)

While there are some data for Stage II patients suggesting harm from 5-FU alone in MSI-H patients there has been...posted by: Richard Goldberg, MD

Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis (Cellceutix)

Mucositis prevention is an extremely important unmet need in a variety of situations as highlighted in radiation...posted by: Dean Gesme, MD

Tagrisso Met Primary Endpoint In Phase III 2nd-Line Lung Cancer Trial (AstraZeneca plc)

A very appropriate response, however, I would like to sound one warning and that is the test used to identify...posted by: Gary Spitzer






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Navigating Cancer has 1 job posted.


Bayer Pharmaceuticals has 1 job posted.


Touchpoint Solutions has over 20 jobs posted.


Check out the OBR Job Board here.





The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
CLBS +949.70%
VSTM +13.85%
ARIA +12.47%
ARGS -16.87%
ALPMY -8.70%
NYMX -6.82%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: August 9, 2016
Company: Merck
Product: Keytruda® (pembrolizumab)

Date: September 1, 2016
Company: Blincyto® (blinatumomab)
Product: Amgen Inc.

Date: September 10, 2016
Company: Genmab A/S / Novartis
Product: Arzerra® (ofatumumab)

See All OBR Radar items»